Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU

Frontiers in Public Health

Public Health

SungKyung Lee¹  Jong Hyuk Lee² 

[1] Center for Growth Engine Industries, Korea Institute for Industrial Economics and Trade (KIET), Sejong, Republic of Korea;College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea;

关键词: cell and gene therapy;    regulation;    reimbursement;    industrial policy;    pricing;    regulatory harmonization;    innovative medicine;    patient accessibility;   

DOI  :  10.3389/fpubh.2023.1109873

 received in 2022-11-28, accepted in 2023-02-01,  发布年份 2023

来源: Frontiers

【 摘 要 】

Ever since relevant bioengineering technologies have sufficiently matured to the platformizable commercialization stage, a slew of money has flocked to the cell and gene therapy market over the last few years, resulting in an abundance of clinical studies in the field. Newer modalities have brought up a string of regulatory and legislative tasks, such as developing guidelines and legislative rules to systematically regulate newer pharmaceutical products. Accordingly, another layer of legislation and guidelines tailored for cell and gene therapies has been introduced and is expected to evolve on par with technological progress. Furthermore, authorities have shifted to pricing and reimbursement policies that can share risks for cost and outcome among stakeholders altogether, such as developers and the government, while expanding the accessibility of patients to innovative cell and gene therapies. This review attempts to capture the salient regulatory features of the cell and gene therapy market in the context of South Korea and the European Union and points out where two sovereign entities currently stand on each policy element and how each tackles regulatory challenges. We can observe the converging trend where regulatory, pricing and reimbursement rules of adjoining countries in the supranational union or member countries of a consortium are getting more aligned. Evidently, concerted efforts to share regulatory science knowledge and embrace reference pricing have played their parts. The authors argue that policy priorities should be placed on initiatives to harmonize with other medical authorities to better the rights of patients and clear out the uncertainties of developers, ultimately to share and advance regulatory science and layout forward-looking policies at opportune times.

【 授权许可】

Unknown   
Copyright © 2023 Lee and Lee.